Immunic is progressing its multiple sclerosis (MS) drug towards key Phase 3 data, with the company anticipating the results to be available by the end of the year.

A woman from Sligo living with Multiple Sclerosis (MS) is sharing a message of calm and reassurance for others who have recently received an MS diagnosis.

Recent research findings are providing new insights into Multiple Sclerosis (MS), potentially transforming the understanding and approach to neurodegenerative diseases. The discoveries aim to change how these conditions are conceptualized.

The upcoming four-part thriller series 'Careless' will depict the struggles of living with multiple sclerosis (MS) through the story of a married couple, Angela and Mike, and features rising star Solly McLeod.

A 'life-changing' drug for multiple sclerosis (MS) patients, which can help improve mobility, has been approved for use on the NHS in England. This offers new hope for thousands of individuals living with the condition.

Individuals living with Multiple Sclerosis (MS) share their experiences, emphasizing that children need a present mother more than a perfectly healthy one. They describe MS as a 'mean' condition that is manageable.

A hospital in Skarżysko-Kamienna, Poland, is limiting its treatment program for multiple sclerosis (MS) patients. This decision is attributed to delays in payments from the National Health Fund (NFZ) and the necessity of financing medications through credit.

Immunic, a biopharmaceutical company, has successfully secured $400 million in funding to advance its late-stage clinical trials for Multiple Sclerosis (MS) treatments.

A father is undertaking a 450km walk from Donegal to Cork, inspired by his daughter's battle with Multiple Sclerosis (MS) to raise awareness and funds.

Immunic, a biopharmaceutical company, has appointed Mike Bonney, a veteran from Biogen and Cubist, as its new board chair. The appointment comes ahead of a key multiple sclerosis (MS) trial readout.

Scientists are cautioning that prolonged exposure to air pollution may elevate the risk of developing Multiple Sclerosis (MS).

Immunic has secured $400 million in financing, setting the stage for the readout of its phase 3 multiple sclerosis (MS) data.